Skip to main content
Premium Trial:

Request an Annual Quote

Human Genome Sciences Revenues Up, Net Loss Falls

NEW YORK, Feb. 11 (GenomeWeb News) - Rockville, Md.-based Human Genome Sciences reported sharply increased revenues and cut its net loss for the fourth quarter ending Dec. 31, the company said today.


The company's revenues increased to $4.6 million for the quarter, compared to $642,000 for the year-ago period, while recording a net loss of $49 million, or $0.38 per share, computed on a GAAP basis for the quarter, compared to a loss of $60 million for the same period in 2002, or $0.46 per share, the company said in a statement. The company received a one-time license fee relating to an amended agreement signed during the fourth quarter of 2003.


The company had cash and short-term investments totaling $1.26 billion, including $280.8 million of restricted investments, on hand as of Dec. 31.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more